Trials of bevacizumab in breast cancer a safety review

Expert Opinion on Drug Safety

Volumn 11, Issue SUPPL. 1, 2012, Pages

  Kmler, Iben ^a   Nielsen, Dorte Lisbet ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antiangiogenic therapy; Bevacizumab; Breast cancer; Safety

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; GEMCITABINE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER;

ADJUVANT THERAPY; ANEMIA; ANOREXIA; ARTERY THROMBOSIS; ASTHENIA; BLEEDING; BREAST CANCER; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EPISTAXIS; HEADACHE; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; RISK BENEFIT ANALYSIS; STOMATITIS; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; PATIENT SELECTION; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84858648585     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.594038     Document Type: Review

References (65)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
2. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8
3. Birk DM, Barbato J, Mureebe L, et al. Current insights on the biology and clinical aspects of VEGF regulation. Vasc Endovascular Surg 2008;42:517-30
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42 (Pubitemid 38702844)
5. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19
6. Bertino EM, Otterson GA. Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. Lung Cancer 2010;70:233-46
7. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-24 (Pubitemid 37433402)
8. Yanagisawa M, Yorozu K, Kurasawa M, et al. Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs 2010;21:687-94
9. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
10. Klencke BJ, Bhattacharya S, Samant MK, et al. Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC). J Clin Oncol 2008;26(20 Suppl):abstract 1036
11. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60
12. Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol 2010;22:595-602
13. Lang I, Inbar MJ, Greil R, et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. J Clin Oncol 2010;28(15s):abstract 1126
14. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9 (Pubitemid 46224178)
15. Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist 2007;12:375-89 (Pubitemid 46698715)
16. Brufsky A, Rivera RR, Hurvitz SA, et al. Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2010;28(15):abstract 1021
17. Brufsky A, Bondarenko IN, Smirnov V, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. San Antonio Breast Cancer Symposium, 2009, oral presentation Available from: http://sabcs09.m2usa. com/sabcsol.html. 2009
18. O'Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010;28(15S):abstract 1005
19. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). Cancer Res 2010;70(Suppl 24):abstract S4-6
20. Derleth C, Mayer IA. Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer 2010;10(Suppl 1):E23-31
21. Nielsen DL, Andersson M, Andersen JL, Kamby C. Antiangiogenic therapy for breast cancer. Breast Cancer Res 2010;12:209
22. Sanborn RE, Sandler AB. The safety of bevacizumab. Expert Opin Drug Saf 2006;5:289-301 (Pubitemid 43379626)
23. Higa GM, Abraham J. Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther 2009;9:999-1007
24. Sirohi B, Smith K. Bevacizumab in the treatment of breast cancer. Expert Rev Anticancer Ther 2008;8:1559-68
25. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47
26. McKinney M, Daly R. 'The more you look..' Adverse-events tools may underestimate numbers. Mod Healthc 2011;41:8-9
27. Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010;23:460-8
28. Nasim S, Sousa BA, Dent RA, Pritchard KI. A meta-analysis of risk of cardiovascular events in patients with metastatic breast cancer (MBC) treated with anti vascular endothelial growth factor (VEGF) therapy-bevacizumab. Cancer Res 2010;70(Suppl 24):abstract P6-12-01
29. Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010;79:27-38
30. Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011;29:1757-64
31. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010;49:287-97
32. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011;29:632-8
33. Verma N, Swain SM. Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side? J Clin Oncol 2011;29:603-6
34. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137-43
35. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50 (Pubitemid 44917502)
36. Morris PG, Dickler M, McArthur HL, et al. Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol 2009;27:6117-23
37. Miller KD, O'Neill A, Perez EA, et al. Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). J Clin Oncol 2008;26(20 Suppl):abstract 520
38. Hart LL, Badarinath S, Waterhouse DM, et al. A multicenter study of 3 docetaxel regimens with bevacizumab as adjuvant therapy for breast cancer (BC): preliminary results. J Clin Oncol 2008;26(20 Suppl):abstract 575
39. Mayer EL, Miller KD, Rugo HS, et al. A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer. J Clin Oncol 2008;26(20 Suppl):abstract 519
40. Roman CD, Choy H, Nanney L, et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 2002;105:43-7 (Pubitemid 34713210)
41. Erinjeri JP, Fong AJ, Kemeny NE, et al. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 2011;117:1296-301
42. Kriegel I, Fourchotte V, Cottu PH, et al. Wound healing and catheter thrombosis after implantable venous access device placement in 266 metastatic breast cancer patients treated with bevacizumab. Cancer Res 2010;70(Suppl 24):abstract P2-16-09
43. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-77 (Pubitemid 46622044)
44. Golshan M, Garber JE, Gelman R, et al. Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol 2010;18:733-7
45. Carpenter JT, Forero A, Falkson CI, et al. Concurrent and sequential bevacizumab and preoperative chemotherapy in the treatment of locally advanced breast cancer: UAB 0493. Cancer Res 2010;70(Suppl 24):abstract P1-11-24
46. Bose D, Meric-Bernstam F, Hofstetter W, et al. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 2010;11:373-82
47. Forero-Torres A, Saleh MN, Galleshaw JA, et al. Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancer. Clin Breast Cancer 2010;10:275-80
48. Ramirez Merino N, Calvo V, Vidal M, et al. Risk of gastrointestinal perforation in patients with metastatic breast cancer treated with bevacizumab: a meta-analysis. J Clin Oncol 2010;28(15S):abstract 1091
49. Sher AF, Wu S. Effect of bevacizumab on the risk of chemotherapy- associated anemia in cancer patients: a meta-analysis. J Clin Oncol 2010;28(15S):abstract 9136
50. Marinella MA, Markert RJ. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern Med J 2009;39:826-34
51. Burki F, Badie K, Bartoli P, et al. Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen. Br J Clin Pharmacol 2008;65:793-4 (Pubitemid 351535098)
52. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305:487-94
53. Kabbinavar F, Shah A. Guidelines for the management of side effect of bevacizumab in patients with colorectal cancer. Cancer Ther 2008;6:327-40
54. Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010;15:819-25
55. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603
56. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31
57. Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2010;29:83-8
58. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14
59. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-34
60. Hayes DF. Bevacizumab treatment for solid tumors: boon or bust? JAMA 2011;305:506-8
61. Burstein HJ. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol 2011;29:1232-5
62. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010;11:1172-83
63. Etienne-Grimaldi MC, Formento P, Degeorges A, et al. Prospective analysis of the impact of VEGF-A gene polymorphisms on pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol 2011;71:921-8
64. Mayer EL Shak S, Miller K, et al. Prognostic value of genomic analysis after neoadjuvant chemotherapy for breast cancer. Cancer Res 2010;70(Suppl 24):abstract P3-10-13
65. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11:102-25